



Neurotech signs design agreement with German company eemagine Medical Imaging Solutions GmbH

Perth, Australia & Malta – 27 November 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has entered into an agreement with eemagine Medical Imaging Solutions GmbH (“eemagine”) to deliver design enhancements to the Company’s Mente Autism headband.

Berlin-based eemagine is a member of the [Neuromotion Group](#) (“Neuromotion”), the holding company for a range of businesses which develop, sell and service equipment and services for the study and treatment of human brain function in clinical and research applications. The group includes ANT Neuro, which has a 20 year history of delivering high performance technologies into the neuroscience and neurodiagnostic fields. These technologies include electroencephalography (“EEG”), magnetoencephalography (“MEG”), magnetic resonance imaging (“MRI”) and transcranial magnetic stimulation (“TMS”). ANT Neuro is the leading provider of such products to research institutions, with applications that span cognitive neuroscience, sport and movement science, neurology and psychiatry.

eemagine is the contract manufacturing arm of Neuromotion and has over ten years of product innovation in the neurotechnology industry. In addition to manufacturing ANT Neuro products and delivering clinical application software, it is responsible for the development, production and support for OEM development projects for third parties and customers worldwide, including several established brands in the neurology industry.

Under the design agreement with Neurotech, eemagine will look to deliver a number of design enhancements to Mente Autism, including investigating the feasibility of incorporating proprietary research grade waveguard™ touch electrodes within the headband, as well as designing the headband to suit varying age ranges of children from 3 to 12 years old, so that the headband can “grow” with the child.

Wolfgang Storf, CEO of Neurotech International said: “We are very excited to engage eemagine, an established leader of cutting edge technology, to review the design of our flagship product Mente Autism and improve on this by leveraging their knowledge and experience. We are continually looking to improve and enhance the Mente product, and this partnership, with a company that services the largest neurotechnology firms in the market, is a clear step towards this commitment. We look forward to updating the market with the outcomes of this work over the coming months.”

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420